MBX-8025

From WikiMD.org
Jump to navigation Jump to search

MBX-8025

MBX-8025 (pronunciation: M-B-X-eight-zero-two-five) is a novel peroxisome proliferator-activated receptor (PPAR) delta agonist developed by CymaBay Therapeutics for the treatment of dyslipidemia and other metabolic disorders.

Etymology

The term "MBX-8025" is a proprietary name given by the developing company, CymaBay Therapeutics. The "MBX" prefix is common to all drugs developed by this company, while "8025" is a unique identifier for this specific drug.

Mechanism of Action

MBX-8025 works by activating the PPAR delta receptors, which are involved in the regulation of lipid metabolism and glucose homeostasis. By activating these receptors, MBX-8025 can help to lower levels of low-density lipoprotein cholesterol (LDL-C) and increase levels of high-density lipoprotein cholesterol (HDL-C), thereby improving the overall lipid profile.

Clinical Trials

MBX-8025 has undergone several clinical trials to evaluate its safety and efficacy in patients with dyslipidemia and other metabolic disorders. Results from these trials have shown that MBX-8025 can significantly reduce levels of LDL-C and increase levels of HDL-C, with a favorable safety profile.

Related Terms

External links

Esculaap.svg

This WikiMD article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski